Prenetics Global (NASDAQ:PRE) CEO Buys $137,325.00 in Stock

Prenetics Global Limited (NASDAQ:PRE) CEO Danny Sheng Wu Yeung purchased 7,500 shares of the company’s stock in a transaction dated Thursday, August 20th. The stock was bought at an average price of $18.31 per share, with a total value of $137,325.00. Following the completion of the transaction, the chief executive officer directly owned 95,235 shares of the company’s stock, valued at approximately $1,743,752.85. This represents a 8.55% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Danny Sheng Wu Yeung also recently made the following trade(s):

• On Monday, August 24th, Danny Sheng Wu Yeung acquired 17,181 shares of Prenetics Global stock. The shares were bought at an average price of $21.23 per share, for a total transaction of $364,752.63.

Prenetics Global Trading Up 8.0%

NASDAQ PRE traded up $1.62 on Monday, reaching $21.82. 417,652 shares of the company were exchanged, compared to its average volume of 135,502. The business’s fifty day moving average price is $19.07 and its 200 day moving average price is $18.90. The stock has a market capitalization of $368.19 million, a P/E ratio of -5.25 and a beta of 0.26. Prenetics Global Limited has a fifty-two week low of $7.18 and a fifty-two week high of $23.63.

Prenetics Global (NASDAQ:PRE) last issued its earnings results on Wednesday, August 19th. The company reported ($0.53) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.84) by $0.31. Prenetics Global had a negative return on equity of 21.41% and a negative net margin of 47.43%.The business had revenue of $46.49 million during the quarter, compared to the consensus estimate of $49.85 million. Equities research analysts forecast that Prenetics Global Limited will post -1.86 earnings per share for the current year.

Institutional Trading of Prenetics Global

Hedge funds and other institutional investors have recently modified their holdings of the business. Operose Advisors LLC purchased a new stake in Prenetics Global in the 2nd quarter valued at about $129,000. Renaissance Technologies LLC increased its position in shares of Prenetics Global by 85.1% during the first quarter. Renaissance Technologies LLC now owns 31,322 shares of the company’s stock valued at $605,000 after acquiring an additional 14,400 shares during the last quarter. State of Wyoming acquired a new stake in shares of Prenetics Global during the first quarter valued at about $48,000. Stevens Capital Partners raised its stake in shares of Prenetics Global by 54.6% in the 1st quarter. Stevens Capital Partners now owns 28,147 shares of the company’s stock valued at $544,000 after acquiring an additional 9,940 shares during the period. Finally, Quadrature Capital Ltd acquired a new position in shares of Prenetics Global in the 4th quarter worth approximately $468,000. 25.01% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms recently issued reports on PRE. Wall Street Zen upgraded shares of Prenetics Global from a “sell” rating to a “hold” rating in a research report on Saturday. Benchmark increased their price target on shares of Prenetics Global from $30.00 to $40.00 and gave the company a “buy” rating in a research note on Wednesday, July 15th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Prenetics Global in a research report on Friday, July 17th. Four equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $34.25.

Prenetics Global Company Profile

Prenetics Global (NASDAQ: PRE) is a molecular diagnostics and genetic testing company that delivers a broad range of laboratory and at-home testing solutions. The company’s core offerings include next-generation sequencing (NGS) panels for hereditary health risks, pharmacogenomic reports to guide medication choices, and comprehensive consumer DNA testing services. In addition to genetic insights, Prenetics provides infectious disease diagnostics—most notably real-time PCR testing for pathogens such as SARS-CoV-2—through an integrated platform that combines sample collection, laboratory processing and digital reporting.

Serving both business-to-consumer and business-to-business markets, Prenetics operates a network of laboratories and service centers across Asia Pacific, Europe, the Middle East and North America.